Sunovion Pharmaceuticals company was known as Sepracor, Inc. until October 12, 2010, later it is acquired by Sumitomo Dainippon Pharma of Japan. So, it is named as Sunovion Pharmaceuticals. It is a pharmaceutical company founded in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler and was originally located in Princeton, New Jersey. It is then re-located to Marlborough, Massachusetts. The company has headquarters in Marlborough, Massachusetts, London, England, Mississauga, Ontario Canada, and Fort Lee, New Jersey.
Sunovion Pharmaceuticals’ mainly focused on the treatment of central nervous system and respiratory disorders, which was directed by Gunnar Aberg, and John McCullough. The Xopenex franchise of drugs is the primary source of revenue for the company. In 2004, insomnia drug Lunesta was approved by the US Food and Drug Administration, which was launched in April 2005.
This growing company offers many effective solutions for the treatment of challenging health conditions. In February 2006 the company has introduced a new drug Brovana to treat chronic obstructive pulmonary disease. Time-by-time it works to innovate the best solutions.
The company announced the acquisition of Cynapsus Therapeutics for approximately $624 million in 2016. The deal added the Parkinson's disease candidate drug to the list of Sunovion Pharmaceuticals products.